Skip to main content
. Author manuscript; available in PMC: 2020 Aug 15.
Published in final edited form as: Cell Chem Biol. 2019 Jun 6;26(8):1143–1158.e6. doi: 10.1016/j.chembiol.2019.05.004

Figure 1. A diagram illustrating systems pharmacology-based prediction of anti-tumor effects of wogonoside in triple-negative breast cancer (TNBC).

Figure 1.

(A) An in silico model for predicting anti-TNBC indications for natural products by integrating the drug-target network and experimentally validated functional genes in TNBC. The performance of the in silico model was evaluated using Receiver Operating Characteristic (ROC) curve. The area under ROC curve (AUC) was shown. (B) The chemical structure clustering analysis for 148 natural products having the significantly predicted anti-TNBC indications (q<10−5). (C) Circos plot (Circo v0.69) representing the predicted anti-TNBC indications (q<10−5) for 24 steroids and 39 flavonoids. The predicted q values with corresponding Z-score are exhibited as connected lines (edges). Natural products with previously published experimental data in TNBC are highlighted in bold font. Wogonside was selected for experimental validation using subject matter expertise based on a combination of factors (see Data S1 for references). (D) Effect of wogonoside on MDA-MB-231 tumor growth in nude mice. (E) The tumor weight of control and wogonoside treatment group (n=7) was measured after 15 days treatment. (F) The tumor volume of control and wogonoside treatment group (n=7) was measured every three days. The comparisons were made relative to the control group and the significance of the difference is indicated as *P value < 0.05 and **P value < 0.01.